Aug 01,2014

Insulet Corporation to Present at the Canaccord Genuity 34th Annual Growth Conference

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the Company will participate in the Canaccord Genuity 34th Annual Growth Conference at the InterContinental Boston. Management is scheduled to present an overview of the Company on Thursday, August 14, 2014 at 1:00 p.m. ET.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Aug 05,2014

Insulet and Dexcom Agree to Develop a CGM-Integrated Personal Diabetes Manager

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, and DexCom, Inc (NASDAQ: DXCM), the leader in continuous glucose monitoring technology, today announced their intention to allow information from Dexcom's 5th generation CGM system to be identified, received and displayed on Insulet's new Bluetooth-enabled Personal Diabetes Manager, currently in development. This project expands upon the initial agreement announced in June to enable the Dexcom mobile app platform to integrate data from Insulet's OmniPod System.

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 06,2014

BD AutoShield™ Duo Pen Needle Now Available through Retail Pharmacies for People with Diabetes

BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the retail pharmacy launch of BD AutoShield™ Duo, the only pen needle with patented dual front and back-end shields that provides greater convenience and safety before and after injecting.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Aug 07,2014

Dexcom Announces Data Integration Relationship with Asante Solutions, Makers of the Snap™ Insulin Pump

Asante Solutions, Inc., manufacturer of the Asante Snap Insulin Pump, and Dexcom announced today their intention to enable the Dexcom mobile app platform, which is currently under development, to integrate and display insulin data from the Asante Snap Insulin Pump. This will be the second insulin delivery device to be integrated into the Dexcom mobile app, which is designed to aggregate glucose and other diabetes-related data from patients' devices and display the integrated data on a smartphone.

COLLABORATION PARTNERSHIP

#connected device

#mobile app

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 07,2014

Insulet Reports Second Quarter 2014 Results

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced financial results for the three and six months ended June 30, 2014. Second quarter 2014 revenue increased 20% to $72.0 million, compared to $60.1 million in the second quarter of 2013. Gross profit for the second quarter of 2014 rose 33% to $35.8 million from $26.8 million for the second quarter of 2013. The Company reached 50% gross margin for the second quarter of 2014, compared to 45% for the second quarter of 2013.

View Analyst & Ambassador Comments
Go to original news
Aug 15,2014

Insulet Appoints Timothy J. Scannell to Board of Directors

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the appointment of Timothy J. Scannell to the Company's board of directors. A seasoned senior medical device executive, Mr. Scannell currently serves as Group President, MedSurg & Neurotechnology at Stryker Corporation.

View Analyst & Ambassador Comments
Go to original news
Sep 03,2014

Sanofi launches mobile game for kids with type 1 diabetes in the UK

Sanofi Diabetes, a division of Sanofi-Aventis, has launched a new mobile game for iOS and Android phones in the United Kingdom. The game, called Mission T1D, is meant to be educational, to teach children as well as their parents, caregivers, and friends about Type 1 diabetes.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 10,2014

Allscripts Ex-CEO Glen Tullman Launches Livongo Health At Disrupt, Backed By General Catalyst

Diabetes affects 29.1 million people in the U.S. — including the son of Allscripts former chief executive Glen Tullman. When Tullman was looking to launch his next startup, he wanted to create a technology that would touch millions, and from his own experience he knew how broken the system of care for diabetes patients was.

View Analyst & Ambassador Comments
Go to original news
Sep 15,2014

Making patient engagement meaningful (to the doctor)

Glen Tullman's new company - Livongo - seeks to empower those with chronic conditions and bring providers into the loop only when they're needed. Tullman says the Livongo platform is ideal for healthcare providers "who don't want to be data geeks." It pulls them into the consumer's orbit only when necessary – when the consumer has a question or the data indicates an intervention is needed – and that's it.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Sep 18,2014

Omada Health raises $950K to serve low income populations

San Francisco-based Omada Health has received $950,000 from the California Health Care Foundation (CHCF) and The Kresge Foundation to expand its prediabetes program, called Prevent, to low income populations in the US. CHCF contributed $450,000 through its CHCF Health Innovation Fund and Kresge Foundation contributed $500,000 through its Social Investment Practice. Omada Health will use the funds to conduct Prevent pilots in certain low income clinics.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES